CN101573604A - 模拟眼环境的装置和方法 - Google Patents
模拟眼环境的装置和方法 Download PDFInfo
- Publication number
- CN101573604A CN101573604A CNA2007800489590A CN200780048959A CN101573604A CN 101573604 A CN101573604 A CN 101573604A CN A2007800489590 A CNA2007800489590 A CN A2007800489590A CN 200780048959 A CN200780048959 A CN 200780048959A CN 101573604 A CN101573604 A CN 101573604A
- Authority
- CN
- China
- Prior art keywords
- test surfaces
- recessed
- protruding
- hole
- periphery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000012360 testing method Methods 0.000 claims description 158
- 239000003814 drug Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 15
- -1 bisfilcon A Chemical compound 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 9
- 230000000474 nursing effect Effects 0.000 claims description 6
- MMWFQFGXFPTUIF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C MMWFQFGXFPTUIF-UHFFFAOYSA-N 0.000 claims description 5
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 claims description 4
- 229920001616 Polymacon Polymers 0.000 claims description 4
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 claims description 4
- GNTAAQBKCCJXGF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one methyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C GNTAAQBKCCJXGF-UHFFFAOYSA-N 0.000 claims description 3
- SVKHOOHZPMBIGM-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO SVKHOOHZPMBIGM-UHFFFAOYSA-N 0.000 claims description 3
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 claims description 3
- KKOWZRLUUCIGQY-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C KKOWZRLUUCIGQY-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 4
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 2
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 2
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 2
- USCSJAIWXWYTEH-UHFFFAOYSA-N 7-[3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one Chemical compound C1=CC=2C(C)=C(C)C(=O)OC=2C=C1OCCCN(CC1)CCN1CC1=CC=C(Cl)C=C1 USCSJAIWXWYTEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 2
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 229960003792 acrivastine Drugs 0.000 description 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 2
- 229960003790 alimemazine Drugs 0.000 description 2
- 229960002469 antazoline Drugs 0.000 description 2
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229960000383 azatadine Drugs 0.000 description 2
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- 229960000325 emedastine Drugs 0.000 description 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 2
- 229950002420 eucatropine Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 229960003630 ketotifen fumarate Drugs 0.000 description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
- 229960001120 levocabastine Drugs 0.000 description 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 2
- 229960001508 levocetirizine Drugs 0.000 description 2
- 229960001474 meclozine Drugs 0.000 description 2
- 229960005042 mequitazine Drugs 0.000 description 2
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 2
- 229960001869 methapyrilene Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960005419 nitrogen Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- 229960001190 pheniramine Drugs 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229950010674 picumast Drugs 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 229960000337 tetryzoline Drugs 0.000 description 2
- 229960001128 triprolidine Drugs 0.000 description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- PVISMVGVPWOQMG-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C PVISMVGVPWOQMG-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- IYSYPCSSDZBWHN-UHFFFAOYSA-N Nor-ketotifen Chemical compound C1=2C=CSC=2C(=O)CC2=CC=CC=C2C1=C1CCNCC1 IYSYPCSSDZBWHN-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000011354 acetal resin Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920000090 poly(aryl ether) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229920002397 thermoplastic olefin Polymers 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01M—TESTING STATIC OR DYNAMIC BALANCE OF MACHINES OR STRUCTURES; TESTING OF STRUCTURES OR APPARATUS, NOT OTHERWISE PROVIDED FOR
- G01M11/00—Testing of optical apparatus; Testing structures by optical methods not otherwise provided for
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/44—Resins; Plastics; Rubber; Leather
- G01N33/442—Resins; Plastics
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eye Examination Apparatus (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Instructional Devices (AREA)
- Prostheses (AREA)
Abstract
本发明公开了用于模拟眼环境中所含镜片的应用的方法和装置。
Description
相关申请
本申请是2006年10月31日提交的美国序列号60/855,433临时申请的非临时申请。
发明领域
本发明涉及模拟眼环境以能够测试镜片的装置和方法。
背景
大多数的眼病使用包含药剂的局部眼用溶液治疗。已经假定如果药剂掺入到镜片中并且这些镜片用作药物递送装置，这些药物的递送和功效将会极大地增加。这些药剂可以通过许多方法添加到镜片中，包括将药物浸入成型的镜片中，在镜片形成前将药剂添加到镜片的制剂中等等。已经假定测试这类药剂向镜片或从镜片吸收和释放率的方法。这些方法包括将镜片置于溶液中并随时间监测药剂的浓度。即使这些方法有用，由于测试中所用溶液的体积，其条件不会模拟当嵌入眼环境时镜片暴露的条件。
在眼环境中，在镜片使用期间非常少量的泪液通过镜片。因此如果人们能够模拟这些条件来测试镜片的性能其将会是有益的。该需要通过下述发明来满足。
附图简述
图1显示阳模(male mold)的透视图。
图2显示阴模(female mold)的透视图。
图3显示配合的装置的闭合横断面图。
图4显示阳模的透视图。
图5显示阴模的透视图。
图6显示配合的装置的横断面图。
图7显示配合的装置的闭合横断面图。
发明详述
本发明包括含有阳模和阴模的用于测试镜片的装置，
其中所述阳模包含凸测试面、外阳面(outer male surface)、从凸测试面的周边延伸的阳座脊(male seating ridge)和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面(outer female surface)、凹测试面、从凹测试面的周边延伸的阴座脊(female seating ridge)和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳(male)凸测试面和阴(female)凹测试面之间形成测试区。
本发明的实施方案显示于下列附图中：
图1，阳模100的透视图，包含凸测试面120，孔160，和阳座脊180。图2，阴模200的透视图，包含凹测试面220，孔260，和阴座脊280。图3，配合的装置的闭合横断面图，配合的的凸测试面120和凹测试面220，在这些表面间限定了测试区300。优选凸和凹测试面具有模拟眼睛和眼睑形状的尺寸和形状。测试区300足够大以容纳镜片(未显示)和一定体积的溶液。优选测试区具有容纳镜片和约50μL至约500μL的溶液，更优选地，约100μL至约400μL的溶液，最优选约200μL的溶液的尺寸。
装置的凸或凹测试面可以包含为小量溶液通过包含于测试区中的镜片表面提供途径的槽。这些槽可以是任意数量或方向，但优选凸或凹测试面包含至少一个横向槽(latitudinal groove)和一个径向槽(radialgroove)。优选这种槽在凸或凹测试面相交于一点。在下列附图显示的本发明实施方案中凸和凹测试面都包含径向和横向槽。
图4，阳模10的透视图，包含凸测试面12，四条径向槽14，孔16，阳座脊18，和六条同心的横向槽19。图5，阴模20的透视图，包含凹测试面22，四条径向槽24，孔26，阴座脊28，和九条同心的横向槽29。凸测试面上的径向槽与横向槽相交以便使流经孔的溶液更容易地流向整个凸测试面。该结构排列也存在于凹测试面上。每个测试面可以包含相同或不同数量的径向槽。优选每个测试面包含至少两个径向槽，更优选三个径向槽，最优选四个径向槽。对于横向槽，每个测试面上这些槽的数量可以相同或不同。优选每个测试面包含至少四个横向槽，更优选至少五个横向槽，最优选至少八个横向槽。外凸和凹面可以是相同或不同的形状。在本发明的一个实施方案(未显示)中外阳面是凹的，外阴面是凸的。优选地，凸和凹测试面具有模拟眼睛和眼睑形状的尺寸和形状。
图6，配合的装置的横断面图，具有阳模10，阴模20，外阳面13，外阴面23，阳座脊18和阴座脊28。如图6所示，孔16从外阳面13向凸测试面12和未显示的测试区延伸。另外，孔26从凹测试面22向外阴面23延伸。图7，配合的装置的闭合横断面，配合的的凸测试面12和凹测试面22，在这些表面间限定了测试区30。测试区30足够大以容纳镜片(未显示)和一定体积的溶液。优选测试区具有容纳镜片和约50μL至约500μL的溶液，更优选地，约100μL至约400μL的溶液，最优选约200μL的溶液的尺寸。
本发明的装置可以由耐用的热塑材料制备，例如热塑树脂、聚烯烃和热塑聚酯。这种材料的实例包括但不限于低、中和高密度聚丙烯、聚乙烯及其共聚物，聚-4-甲基戊烯、氟化乙烯丙烯共聚物、乙烯氟乙烯共聚物、缩醛树脂、聚芳醚、聚芳醚砜、尼龙等等。装置可以通过注塑热压成型等制备。
本发明还包括测试包含药剂的眼科装置扩散率的方法，其中该方法包括以下步骤：
(a)将包含药剂的镜片置于包含阳模和阴模的装置的测试区，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳凸测试面和阴凹测试面之间形成测试区，
(b)从外阳面向阳模的孔加入溶液，和
(c)监测从外阴面的孔流出的溶液以测定药剂的存在或不存在。
本文使用的术语阳模、阴模、径向槽、横向槽、测试区、凸测试面和凹测试面如下所述：
本文使用的“药剂”是指用于治疗眼疾病的药物或营养化合物，这类化合物在氧和某些过渡金属的存在下降解。药物化合物的实例包括抗组胺剂，抗生素、抗菌剂、抗病毒剂、抗真菌剂、镇痛药、麻醉剂、抗过敏剂、肥大细胞稳定剂、甾体和非甾体抗炎剂、血管生成抑制剂、抗代谢物、纤溶剂、神经保护药物、血管生成抑制甾体、扩瞳剂、环戊醇胺酯扩瞳剂、缩瞳剂、血管收缩药、血管扩张剂、抗凝固剂、抗癌剂、反义剂、免疫调节剂、碳酸酐酶抑制剂、整联蛋白antabonistsl、环氧合酶抑制剂、VEGF拮抗剂、免疫抑制剂等等。特别地，药物化合物的实例包括但不限于阿伐斯汀、安他唑啉、阿司咪唑、阿扎他定、氮
斯汀、布克力嗪、布比卡因、西替利嗪、氯马斯汀、赛克力嗪、赛庚啶、依巴斯汀、依美斯汀、麻黄碱、尤卡托品、非索非那定、后马托品、羟嗪、酮替芬、左卡巴斯汀、左西替利嗪(levoceterizine)、洛美沙星、美克洛嗪、甲哌卡因、美喹他嗪、甲地嗪、美沙吡林、米安色林、萘甲唑林、去甲阿司咪唑、norebastine、氧氟沙星、羟甲唑啉、非尼拉敏、去氧肾上腺素、毒扁豆碱、匹库马特、异丙嗪、东莨菪碱、特非那定、四氢唑啉(tetrahyerozoline)、硫乙拉嗪、噻吗洛尔、阿利马嗪、曲普利啶、及其药学可接受的盐和混合物。优选的药物化合物包括阿伐斯汀(acrivatine)、安他唑啉、阿司咪唑、阿扎他定、氮
斯汀、氯马斯汀、赛庚啶、依巴斯汀、依美斯汀、尤卡托品、非索非那定、后马托品、羟嗪、酮替芬、左卡巴斯汀、左西替利嗪(levoceterizine)、美克洛嗪、美喹他嗪、甲地嗪、美沙吡林、去甲阿司咪唑、norebastine、羟甲唑啉、依色林、匹库马特、异丙嗪、东莨菪碱、特非那定、四氢唑啉(tetrahyerozoline)、fimilol、阿利马嗪、曲普利啶及其药学可接受的盐。特别优选的药物化合物包括非尼拉敏(phenarimine)、酮替芬、富马酸酮替芬、富马酸nor ketotifen、11-二氢-11-(1-甲基-4-亚哌啶基)-5H-咪唑并[2，1-b][3]苯并氮杂-3-甲醛(CAS号147084-10-4)、奥洛他定及其混合物。更特别优选的药物化合物包括富马酸酮替芬、11-二氢-11-(1-甲基-4-亚哌啶基)-5H-咪唑并[2，1-b][3]苯并氮杂
-3-甲醛(CAS号147084-10-4)及其混合物。
营养化合物的实例包括维生素和补充物，例如维生素A、D、E、叶黄素、玉米黄素、硫辛酸、黄酮类、适合眼用(ophthalmicially compatible)的脂肪酸、例如ω3和ω6脂肪酸、其组合物、与药物化合物的组合物等等。本发明的方法可以用于检测含有约8μg或更多药剂的镜片的释放率(或吸收率)。优选地，含有约8μg至约90μg、更优选约10μg至约40μg、更优选约10μg至约25μg的镜片的释放率可以通过本发明的方法测定。
本文使用的“镜片”是指存在于眼睛内或眼睛上的装置。这些装置可以提供视力矫正或是化妆用的。眼科装置包括但不限于软性隐形眼镜、眼内透镜、覆盖式镜片、眼睛嵌入剂和光学嵌入剂。本发明优选的眼科装置是由硅酮弹性体或水凝胶制备的软性隐形眼镜，其包括但不限于硅酮水凝胶和氟代水凝胶。软性隐形眼镜制剂公开于美国专利号5,710,302、WO 9421698、EP 406161、JP 2000016905、美国专利号5,998,498、美国专利号6,087,415、美国专利号5,760,100、美国专利号5,776,999、美国专利号5,789,461、美国专利号5,849,811和美国专利号5,965,631中。上述参考文献其整体引入作为参考。本发明特别优选的眼科装置是以acofilcon A、alofilcon A、alphafilcon A、amifilcon A、astifilconA、atalafilcon A、balafilcon A、bisfilcon A、bufilcon A、comfilcon、crofilconA、cyclofilcon A、darfilcon A、deltafilcon A、deltafilcon B、dimefilcon A、drooxifilcon A、epsifilcon A、esterifilcon A、etafilcon A、focofilcon A、genfilcon A、govafilcon A、hefilcon A、hefilcon B、hefilcon D、hilafilconA、hilafilcon B、hioxifilcon B、hioxifilcon C、hixoifilcon A、hydrofilconA、lenefilcon A、licryfilcon A、licryfilcon B、lidofilcon A、lidofilcon B、lotrafilcon A、lotrafilcon B、mafilcon A、mesifilcon A、methafilcon B、mipafilcon A、nelfilcon A、netrafilcon A、ocufilcon A、ocufilcon B、ocufilcon C、ocufilcon D、ocufilcon E、ofilcon A、omafilcon A、oxyfilconA、pentafilcon A、perfilcon A、pevafilcon A、phemfilcon A、polymacon、silafilcon A、siloxyfilcon A、tefilcon A、tetrafilcon A、trifilcon A、vifilcon和xylofilcon A的美国批准名已知的。本发明更特别优选的眼科装置是genfilcon A、lenefilcon A、comfilcon、lotrafilcon A、lotraifilcon B和balafilcon A。最优选的镜片包括etafilcon A、nelfilcon A、hilafilcon、vifilcon和polymacon。
本发明方法中所用的“溶液”可以是基于水的溶液。模拟天然泪液膜的溶液是优选的。典型的溶液包括，但不限于，盐溶液、其它缓冲液和去离子水。优选的含水溶液是去离子水或含盐的盐溶液，所述的盐包括但不限于氯化钠、硼酸钠、磷酸钠、磷酸氢二钠、磷酸二氢钠，或者它们相应的钾盐。这些成分通常组合形成含有酸及其共轭碱的缓冲液，以便酸和碱的加入只会引起相对小的pH变化。缓冲液还可以包括2-(N-吗啉代)乙磺酸(MES)、氢氧化钠、2，2-双(羟甲基)-2，2’，2”-次氮基三乙醇、正三(羟甲基)甲基-2-氨基乙磺酸、柠檬酸、柠檬酸钠、碳酸钠、碳酸氢钠、乙酸、乙酸钠、乙二胺四乙酸等及其组合物。
本文使用的“监测”是指分析溶液以测定溶液中药剂浓度的方法。这类检测方法的实例包括但不限于HPLC、UV光谱法等等。
本发明还包括测量药剂向镜片吸收率的方法，其中该方法包括以下步骤：
(a)将包含镜片置于包含阳模和阴模的装置的测试区，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳凸测试面和阴凹测试面之间形成测试区，
(b)从外阳面向阳模的孔加入含有药剂的溶液，和
(c)监测从外阴面的孔流出的溶液以测定药剂的存在或不存在。
本文使用的术语阳模、阴模、径向槽、横向槽、测试区、凸测试面、凹测试面、药剂、镜片、溶液和监测如上所述。
存在人们希望测试镜片在眼环境中的性能，而不是所述镜片包含药剂的其他情况。例如如果人们想要测定溶液的表面活性剂、赋形剂、防腐剂、湿润剂或其它成分(“眼睛护理溶液成分”)是否被镜片吸收，拥有模拟镜片在眼环境中性能的测试会是有用的。鉴于这种需要，本发明包括测量眼护理溶液成分向镜片吸收率的方法，其中该方法包括以下步骤：
(a)将镜片置于包含阳模和阴模的装置的测试区，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳凸测试面和阴凹测试面之间形成测试区，
(b)从外阳面向阳模的孔加入含有眼护理溶液成分的溶液，和
(c)监测从外阴面的孔流出的溶液以测定眼护理溶液成分的存在或不存在。
本文使用的术语阳模、阴模、径向槽、横向槽、测试区、凸测试面、凹测试面、眼睛护理溶液成分、镜片、溶液和监测如上所述。
本发明装置和方法的具体实施方案显示但不限制本发明。它们只是用于建议实施本发明的方法。熟悉隐形眼镜以及其它专业的技术人员可能发现实施本发明的其它方法。但是，这些方法被认为在本发明的范围内。
Claims (25)
1.包含阳模和阴模的用于测试镜片的装置，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳凸测试面和阴凹测试面之间形成测试区。
2.权利要求1的装置，其中所述凸测试面包含至少一个从孔向凸测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
3.权利要求2的装置，其中所述凸测试面包含至少四个径向槽。
4.权利要求2的装置，其中所述凸测试面包含至少四个横向槽。
5.权利要求1的装置，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
6.权利要求5的装置，其中所述凹测试面包含至少两个径向槽。
7.权利要求5的装置，其中所述凹测试面包含至少四个横向槽。
8.权利要求5的装置，其中所述凹测试面包含至少四个径向槽。
9.权利要求2的装置，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
10.权利要求9的装置，其中所述凸测试面包含至少两个径向槽和至少三个横向槽，所述凹面包含至少两个径向槽和至少三个横向槽。
11.测试包含药剂的眼科装置扩散率的方法，其中该方法包括以下步骤：
(a)将包含药剂的镜片置于包含阳模和阴模的装置的测试区，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳凸测试面和阴凹测试面之间形成测试区，
(b)从外阳面向阳模的孔加入溶液，和
(c)监测从外阴面的孔流出的溶液以测定药剂的存在或不存在。
12.权利要求11的方法，其中所述镜片选自acofilcon A、alofilconA、alphafilcon A、amifilcon A、astifilcon A、atalafilcon A、balafilcon A、bisfilcon A、bufilcon A、comfilcon、crofilcon A、cyclofilcon A、darfilconA、deltafilcon A、deltafilcon B、dimefilcon A、drooxifilcon A、epsifilconA、esterifilcon A、etafilcon A、focofilcon A、genfilcon A、govafilcon A、hefilcon A、hefilcon B、hefilcon D、hilafilcon A、hilafilcon B、hioxifilconB、hioxifilcon C、hixoifilcon A、hydrofilcon A、lenefilcon A、licryfilconA、licryfilcon B、lidofilcon A、lidofilcon B、lotrafilcon A、lotrafilcon B、mafilcon A、mesifilcon A、methafilcon B、mipafilcon A、nelfilcon A、netrafilcon A、ocufilcon A、ocufilcon B、ocufilcon C、ocufilcon D、ocufilconE、ofilcon A、omafilcon A、oxyfilcon A、pentafilcon A、perfilcon A、pevafilcon A、phemfilcon A、polymacon、silafilcon A、siloxyfilcon A、tefilcon A、tetrafilcon A、trifilcon A、vifilcon和xylofilcon A。
13.权利要求11的方法，其中所述凸测试面包含至少一个从孔向凸测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
14.权利要求11的方法，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
15.权利要求15的方法，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
16.权利要求13的方法，其中所述凸测试面包含至少两个径向槽和至少三个横向槽，并且所述凹面包含至少两个径向槽和至少三个横向槽。
17.测量药剂向镜片吸收率的方法，其中该方法包括以下步骤：
(a)将镜片置于包含阳模和阴模的装置的测试区，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在阳凸测试面和阴凹测试面之间形成测试区，
(b)从外阳面向阳模的孔加入含有药剂的溶液，和
(c)监测从外阴面的孔流出的溶液以测定药剂的存在或不存在。
18.权利要求17的方法，其中镜片选自acofilcon A、alofilcon A、alphafilcon A、amifilcon A、astifilcon A、atalafilcon A、balafilcon A、bisfilcon A、bufilcon A、comfilcon、crofilcon A、cyclofilcon A、darfilconA、deltafilcon A、deltafilcon B、dimefilcon A、drooxifilcon A、epsifilconA、esterifilcon A、etafilcon A、focofilcon A、genfilcon A、govafilcon A、hefilcon A、hefilcon B、hefilcon D、hilafilcon A、hilafilcon B、hioxifilconB、hioxifilcon C、hixoifilcon A、hydrofilcon A、lenefilcon A、licryfilconA、licryfilcon B、lidofilcon A、lidofilcon B、lotrafilcon A、lotrafilcon B、mafilcon A、mesifilcon A、methafilcon B、mipafilcon A、nelfilcon A、netrafilcon A、ocufilcon A、ocufilcon B、ocufilcon C、ocufilcon D、ocufilconE、ofilcon A、omafilcon A、oxyfilcon A、pentafilcon A、perfilcon A、pevafilcon A、phemfilcon A、polymacon、silafilcon A、siloxyfilcon A、tefilcon A、tetrafilcon A、trifilcon A、vifilcon和xylofilcon A。
19.权利要求17的方法，其中所述凸测试面包含至少一个从孔向凸测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
20.权利要求17的方法，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
21.权利要求19的方法，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
22.权利要求21的方法，其中所述凸测试面包含至少两个径向槽和至少三个横向槽，并且所述凹面包含至少两个径向槽和至少三个横向槽。
23.测量眼护理溶液成分向镜片吸收率的方法，其中该方法包括以下步骤：
(a)将镜片置于包含阳模和阴模的装置的测试区，
其中所述阳模包含凸测试面、外阳面、从凸测试面的周边延伸的阳座脊和从所述外阳面向所述凸测试面延伸的孔，
其中所述阴模包含外阴面、凹测试面、从凹测试面的周边延伸的阴座脊和从所述凹测试面向所述外阴面延伸的孔，
其中当阳模和阴模配合时，阳座脊位于阴座脊上，并在氧凸测试面和阴凹测试面之间形成测试区，
(b)从外阳面向阳模的孔加入含有眼护理溶液成分的溶液，和
(c)监测从外阴面的孔流出的溶液以测定眼护理溶液成分的存在或不存在。
24.权利要求23的方法，其中所述凸测试面包含至少一个从孔向凸测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
25.权利要求23的方法，其中所述凹测试面包含至少一个从孔向凹测试面的周边延伸的径向槽和至少一个与至少一个径向槽相交的横向槽。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85543306P | 2006-10-31 | 2006-10-31 | |
| US60/855,433 | 2006-10-31 | ||
| PCT/US2007/082584 WO2008055047A2 (en) | 2006-10-31 | 2007-10-26 | Devices and methods to simulate an ocular environment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101573604A true CN101573604A (zh) | 2009-11-04 |
| CN101573604B CN101573604B (zh) | 2013-12-04 |
Family
ID=39154017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800489590A Expired - Fee Related CN101573604B (zh) | 2006-10-31 | 2007-10-26 | 模拟眼环境的装置和方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7793535B2 (zh) |
| EP (1) | EP2078186B1 (zh) |
| JP (1) | JP2010508562A (zh) |
| KR (1) | KR20090094816A (zh) |
| CN (1) | CN101573604B (zh) |
| AR (1) | AR063753A1 (zh) |
| AU (1) | AU2007313797A1 (zh) |
| BR (1) | BRPI0718298A2 (zh) |
| CA (1) | CA2668296C (zh) |
| HK (2) | HK1133297A1 (zh) |
| RU (1) | RU2443999C2 (zh) |
| TW (1) | TWI460417B (zh) |
| WO (1) | WO2008055047A2 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083793A2 (en) * | 2006-10-31 | 2009-08-05 | Johnson and Johnson Vision Care, Inc. | Methods and devices to test diffusion rates of ocular drug delivery systems |
| US7968018B2 (en) * | 2007-04-18 | 2011-06-28 | Coopervision International Holding Company, Lp | Use of surfactants in extraction procedures for silicone hydrogel ophthalmic lenses |
| US8295684B2 (en) * | 2007-10-08 | 2012-10-23 | Sony Computer Entertainment America Inc. | Method and system for scaling content for playback with variable duration |
| US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| US9069186B2 (en) * | 2013-03-15 | 2015-06-30 | Johnson & Johnson Vision Care, Inc. | Thermoformed ophthalmic insert devices |
| KR20200048825A (ko) * | 2018-10-30 | 2020-05-08 | 부산대학교 산학협력단 | 가상현실 기반의 백내장 수술 시뮬레이터 시스템 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817924A (en) * | 1998-01-21 | 1998-10-06 | Modern Controls, Inc. | Method and apparatus for measuring oxygen transmission through contact lenses |
| US6450014B1 (en) * | 1999-12-28 | 2002-09-17 | Eastman Kodak Company | Method and apparatus for measuring osmotic pressure |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601967D0 (en) * | 1986-01-28 | 1986-03-05 | Coopervision Optics | Manufacturing contact lenses |
| US4782946A (en) * | 1987-09-17 | 1988-11-08 | Allergan, Inc. | Soft contact lens hydration device and kit |
| US5115056A (en) | 1989-06-20 | 1992-05-19 | Ciba-Geigy Corporation | Fluorine and/or silicone containing poly(alkylene-oxide)-block copolymers and contact lenses thereof |
| US5374662A (en) | 1993-03-15 | 1994-12-20 | Bausch & Lomb Incorporated | Fumarate and fumaramide siloxane hydrogel compositions |
| TW325744U (en) * | 1993-07-21 | 1998-01-21 | Ciba Geigy Ag | Two-sided contact lens mold |
| US5490415A (en) * | 1994-04-15 | 1996-02-13 | Pharmetrix Corporation | Diffusion test apparatus and method |
| US5760100B1 (en) | 1994-09-06 | 2000-11-14 | Ciba Vision Corp | Extended wear ophthalmic lens |
| TW585882B (en) | 1995-04-04 | 2004-05-01 | Novartis Ag | A method of using a contact lens as an extended wear lens and a method of screening an ophthalmic lens for utility as an extended-wear lens |
| CN1084335C (zh) | 1995-12-07 | 2002-05-08 | 博士伦公司 | 用于降低硅氧烷水凝胶的模量的单体单元 |
| JP3813667B2 (ja) | 1996-09-24 | 2006-08-23 | 株式会社トーメー | コンタクトレンズ用洗浄・消毒用具及びそれを用いたコンタクトレンズの消毒方法 |
| US5998498A (en) | 1998-03-02 | 1999-12-07 | Johnson & Johnson Vision Products, Inc. | Soft contact lenses |
| US6087415A (en) | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
| JP2000016905A (ja) | 1998-07-01 | 2000-01-18 | Tokuriki Kagaku Kenkyusho:Kk | 抗菌抗かび剤および抗菌抗かび材料 |
| ATE310634T1 (de) * | 2001-05-23 | 2005-12-15 | Novartis Pharma Gmbh | Aufnahmekorb für eine ophtalmische linse |
| US6909503B2 (en) * | 2001-08-17 | 2005-06-21 | Novartis Ag | Cuvette for lens inspection |
| DE60326597D1 (de) | 2002-06-05 | 2009-04-23 | Univ Florida | Ophthalmisches arzneimittelabgabesystem |
| US6981403B2 (en) * | 2003-10-31 | 2006-01-03 | Mocon, Inc. | Method and apparatus for measuring gas transmission rates of deformable or brittle materials |
| CA2597219C (en) * | 2005-02-04 | 2014-04-15 | Auburn University | Contact drug delivery system |
| SG177132A1 (en) * | 2005-02-14 | 2012-01-30 | Johnson & Johnson Vision Care | A comfortable ophthalmic device and methods of its production |
| EP2083793A2 (en) * | 2006-10-31 | 2009-08-05 | Johnson and Johnson Vision Care, Inc. | Methods and devices to test diffusion rates of ocular drug delivery systems |
-
2007
- 2007-10-25 US US11/923,680 patent/US7793535B2/en active Active
- 2007-10-26 WO PCT/US2007/082584 patent/WO2008055047A2/en active Application Filing
- 2007-10-26 BR BRPI0718298-8A patent/BRPI0718298A2/pt not_active IP Right Cessation
- 2007-10-26 EP EP07854430.1A patent/EP2078186B1/en not_active Not-in-force
- 2007-10-26 CA CA2668296A patent/CA2668296C/en not_active Expired - Fee Related
- 2007-10-26 KR KR1020097011210A patent/KR20090094816A/ko not_active Application Discontinuation
- 2007-10-26 RU RU2009120559/28A patent/RU2443999C2/ru not_active IP Right Cessation
- 2007-10-26 AU AU2007313797A patent/AU2007313797A1/en not_active Abandoned
- 2007-10-26 JP JP2009535401A patent/JP2010508562A/ja active Pending
- 2007-10-26 CN CN2007800489590A patent/CN101573604B/zh not_active Expired - Fee Related
- 2007-10-30 TW TW096140679A patent/TWI460417B/zh active
- 2007-10-31 AR ARP070104839A patent/AR063753A1/es not_active Application Discontinuation
-
2009
- 2009-11-25 HK HK09111019.5A patent/HK1133297A1/zh not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104340.7A patent/HK1138640A1/zh not_active IP Right Cessation
- 2010-08-05 US US12/851,434 patent/US20100300182A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817924A (en) * | 1998-01-21 | 1998-10-06 | Modern Controls, Inc. | Method and apparatus for measuring oxygen transmission through contact lenses |
| US6450014B1 (en) * | 1999-12-28 | 2002-09-17 | Eastman Kodak Company | Method and apparatus for measuring osmotic pressure |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0718298A2 (pt) | 2013-12-03 |
| KR20090094816A (ko) | 2009-09-08 |
| TW200837342A (en) | 2008-09-16 |
| HK1138640A1 (zh) | 2010-08-27 |
| AR063753A1 (es) | 2009-02-18 |
| US7793535B2 (en) | 2010-09-14 |
| US20100300182A1 (en) | 2010-12-02 |
| EP2078186B1 (en) | 2014-05-07 |
| RU2009120559A (ru) | 2010-12-10 |
| CA2668296C (en) | 2015-12-29 |
| CN101573604B (zh) | 2013-12-04 |
| CA2668296A1 (en) | 2008-05-08 |
| RU2443999C2 (ru) | 2012-02-27 |
| HK1133297A1 (zh) | 2010-03-19 |
| WO2008055047A2 (en) | 2008-05-08 |
| EP2078186A2 (en) | 2009-07-15 |
| TWI460417B (zh) | 2014-11-11 |
| AU2007313797A1 (en) | 2008-05-08 |
| JP2010508562A (ja) | 2010-03-18 |
| WO2008055047A3 (en) | 2008-06-26 |
| US20080100795A1 (en) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101573604B (zh) | 模拟眼环境的装置和方法 | |
| US20240142666A1 (en) | Comfortable ophthalmic device and methods of its production | |
| CN108463323A (zh) | 带腔可调节透镜 | |
| CN104614873A (zh) | 用于治疗眼变态反应性的方法和眼科装置 | |
| EP3144720A2 (en) | Contact lens product | |
| CN110650734A (zh) | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 | |
| EP2046872A2 (en) | Packages for ophthalmic lenses containing pharmaceutical agents | |
| CN101573102B (zh) | 测试眼部药物递送系统扩散率的方法和装置 | |
| TW201916891A (zh) | 具有抗敏舒緩效果的眼用產品 | |
| CN109718376B (zh) | 具有抗敏舒缓效果的眼用产品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1138640 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1138640 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 Termination date: 20161026 |